BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong

Antengene Secures Expanded Approvals For Xpovio In Hong Kong Across Multiple Myeloma And DLBCL

- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for mul...

December 04, 2025 | News

Antengene Secures NMPA Approval for IND of CLINCH Two Combination Study in Gastric Cancer

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...

December 03, 2025 | News

Ascletis Advances First Oral Triple Agonist for Obesity, ASC37, into Clinical Development

- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability ...

December 01, 2025 | News

IASO Bio Achieves Landmark Hong Kong Approval for Fucaso CAR-T Therapy

IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commerciali...

November 28, 2025 | Regulatory

ToolGen and GenEditBio Join Forces to Advance Next Generation In Vivo Genome Editing

Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-...

November 25, 2025 | News

Akeso Receives NMPA Clearance to Initiate Clinical Trials for China’s First Bispecific Antibody for Alzheimer’s Disease

Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and blood-brain barrier (BBB) expre...

November 18, 2025 | News

Akeso Initiates First-in-Human Trial of Personalised mRNA Vaccine AK154 for Pancreatic Cancer

Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vacc...

November 11, 2025 | News

Tenpoint Therapeutics and Zhaoke Ophthalmology Advance BRIMOCHOL™ PF Toward Global Market with NDA Filing in South Korea

Submission of New Drug Application (NDA) in South Korea by Zhaoke Ophthalmology Ltd.’s local partner, Kwangdong Pharmaceutical Co., Ltd., marks the...

November 07, 2025 | News

Hasten Biopharmaceutical Completes 70 Marketing Authorization Transfers and Builds End-to-End Commercial Network Across Asia-Pacific

Hasten Biopharmaceutical Co., Ltd. ("Hasten") announced that while completing 70 Marketing Authorization Transfers (MAT) for its Asia-Pacific pro...

November 05, 2025 | News

Novo Nordisk Launches Wegovy® in Hong Kong to Tackle Rising Obesity Rates with Proven Long-Term Weight Management Therapy

Wegovy® (semaglutide) is a once-weekly injectable prescription medicine used in combination with a reduced calorie diet and increased physical a...

November 04, 2025 | News

Nielsen BioSciences and Maruho Expand Licensing Agreement for CANDIN Across Key Asian Markets

Expansion of licensing agreement extends CANDIN’s development to key Asian growth markets including China, South Korea and Taiwan--and broadens the...

October 27, 2025 | News

Venus Medtech Completes Patient Enrollment in Cardiovalve TARGET Study for Tricuspid Valve Replacement

Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") announced the successful completion of patient enrollmen...

October 27, 2025 | News

Alphamab Oncology and CSPC’s HER2-Targeting ADC JSKN003 Receives Breakthrough Therapy Designation in China for Advanced Colorectal Cancer

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targ...

October 21, 2025 | News

Ascletis Completes U.S. Phase IIa Enrollment for Once-Monthly ASC30 GLP-1 Depot Therapy in Obesity

The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) d...

October 20, 2025 | News

Stay Connected